QNZ (EVP4593)

Research use only, not for human use.

QNZ (EVP4593) shows potent inhibitory activity toward both NF-κB activation and TNF-α production with IC50 of 11 nM and 7 nM, respectively.

QNZ (EVP4593) shows potent inhibitory activity toward both NF-κB activation and TNF-α production with IC50 of 11 nM and 7 nM, respectively.

QNZ (Compound 11q) has a suppressing effect of the NF-κB mediated-inflammatory response. QNZ inhibits edema formation dose-dependently. QNZ (EVP4593) reduces the number of lysosomes/autophagosomes and store-operated channel (SOC) currents in Huntington's disease (HD). Normalization of calcium transport within neurons in response to QNZ is expect to reduce pathology manifestation. A number of lysosomes/autophagosomes are evaluated in HD and WT neurons treated with QNZ using transmission electron microscopy (TEM). Incubation with QNZ reduces the number of lysosomes/autophagosomes in HD GABAergic medium spiny (GABA MS)-like neurons (GMSLNs) by almost two-fold (from 0.41±0.04 to 0.23±0.04; p<0.05), while WT neurons are not affected. This observation is confirmed by examining lysosome content by flow cytometry (FC) analysis. The median fluorescence intensity is reduced by 34±6 % in HD GMSLNs upon QNZ treatment (p<0.05).

——

CAY10470

Apoptosis

NF-κB

NF-κB| TNF-α

Inflammation/Immunology

——

545380-34-5

356.42

C22H20N4O

>98% (HPLC)

DMSO: 5 mg/mL (14.02 mM)

NC1=CC2=C(N=CN=C2NCCC3=CC=C(OC4=CC=CC=C4)C=C3)C=C1

N4-(4-phenoxyphenethyl)quinazoline-4,6-diamine

(-20℃)

With Ice Pack

≥ 2 years